Target intelligence / Profile preview

Mitochondrial glycine transporter (SLC25A38)

Target
SLC25A38
Molecular classification
Transporter, Solute carrier (SLC) family protein, Mitochondrial carrier protein
01

Overview

Mitochondrial glycine transporter (SLC25A38) is a member of the solute carrier (SLC25) family located in the inner mitochondrial membrane. Its primary physiological function is to import glycine into mitochondria, an essential step for heme biosynthesis, since glycine is a substrate for δ-aminolevulinic acid (ALA) synthesis—the first and rate-limiting step in the heme pathway. Mutations in SLC25A38 are the leading genetic cause of autosomal recessive congenital sideroblastic anemia, a severe, transfusion-dependent disease associated with iron overload. SLC25A38 is also emerging as a prognostic biomarker in certain cancers, with altered expression correlating with disease progression in uveal melanoma and possibly other tumors. There are currently no direct small-molecule or biologic drugs targeting SLC25A38; the main therapeutic approaches aim to bypass the defect by supplementing glycine, ALA, or folate to restore heme synthesis.

Other names
SLC25A38Mitochondrial glycine transporter GlyCAppoptosinFLJ20551SIDBA2GlyCmitochondrial glycine transportersolute carrier family 25 member 38
02

Mechanism of action

Glycine or ALA supplementation aims to overcome the block in heme synthesis by providing substrates downstream of the defective transporter.

03

Biological functions

Heme synthesisAmino acid (glycine) transport into mitochondriaRedox biologyMitochondrial metabolism
04

Disease associations

Congenital sideroblastic anemiaIron overload disorders (via anemia-associated secondary iron loading)Potential prognostic marker in cancer (e.g., uveal melanoma, hepatocellular carcinoma)
05

Safety considerations

Potential risk of iron overload with ineffective erythropoiesis in congenital sideroblastic anemiaResistance or lack of response to therapy in some model systems (e.g., incomplete correction with glycine or ALA alone in vertebrates)
06

Interacting drugs

glycine

2 more in the full profile.

07

Biomarkers

SLC25A38 expression (as a molecular marker for some cancers—e.g., uveal melanoma)SLC25A38 genetic mutation (diagnostic marker for congenital sideroblastic anemia)

Beyond the preview

Go deeper on Mitochondrial glycine transporter (SLC25A38).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial glycine transporter (SLC25A38).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call